U. Ohnmacht

703 total citations
20 papers, 539 citations indexed

About

U. Ohnmacht is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, U. Ohnmacht has authored 20 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in U. Ohnmacht's work include Cancer Treatment and Pharmacology (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cancer-related gene regulation (4 papers). U. Ohnmacht is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cancer-related gene regulation (4 papers). U. Ohnmacht collaborates with scholars based in Germany, Spain and United States. U. Ohnmacht's co-authors include M. Arning, C. Stoffregen, Norman Rieger, Christian Manegold, Marius Žemaitis, Jürgen R. Fischer, Harald Lahm, M. Kaufmann, Martin Helsing and K. Possinger and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

U. Ohnmacht

20 papers receiving 534 citations

Peers

Countries citing papers authored by U. Ohnmacht

Since Specialization

Citations

This map shows the geographic impact of U. Ohnmacht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Ohnmacht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Ohnmacht more than expected).

Fields of papers citing papers by U. Ohnmacht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Ohnmacht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Ohnmacht. The network helps show where U. Ohnmacht may publish in the future.

Co-authorship network of co-authors of U. Ohnmacht

This figure shows the co-authorship network connecting the top 25 collaborators of U. Ohnmacht. A scholar is included among the top collaborators of U. Ohnmacht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Ohnmacht. U. Ohnmacht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer 2018 ·Annals of Oncology ·Christophe Massard, (unknown), Jean‐Charles Soria, Ulrik Lassen, Christophe Le Tourneau, Debashis Sarker, Claire Smith, U. Ohnmacht, Gerard J. Oakley, Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón	107
2	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours 2018 ·European Journal of Cancer ·Olivier Mir, Analía Azaro, Jaime R. Merchan, Rashmi Chugh, Jonathan C. Trent, Jordi Rodón, U. Ohnmacht, (unknown), Claire Smith, Eunice Yuen, Gerard J. Oakley, Axel Le Cesne, Jean‐Charles Soria, Karim A. Benhadji, Christophe Massard	23
3	Abstract CT048: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study 2016 ·Cancer Research ·Eunice Yuen, Bharvin K.R. Patel, Claire Smith, Maria M. Posada, Robert L. Bell, U. Ohnmacht, Christophe Massard, Jordi Rodón, Karim A. Benhadji	3
4	First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer 2016 ·European Journal of Cancer ·Christophe Massard, (unknown), J.C. Soria, Ulrik Lassen, C. Le Tourneau, (unknown), U. Ohnmacht, (unknown), Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón	16
5	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer 2015 ·Investigational New Drugs ·Analía Azaro, Jordi Rodón, Antonio Calles, Irene Braña, Manuel Hidalgo, Pedro P. López‐Casas, Manuel Muñoz, Paul Westwood, J. A. Miller, Brian A. Moser, U. Ohnmacht, (unknown), Karim A. Benhadji, Emiliano Calvo	25
6	First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer. 2015 ·Journal of Clinical Oncology ·Christophe Massard, Analía Azaro, Christophe Le Tourneau, Jean‐Charles Soria, Marie Alt, Claire Smith, U. Ohnmacht, (unknown), (unknown), Eunice Yuen, Karim A. Benhadji, Jordi Rodón	3
7	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer 2014 ·Investigational New Drugs ·Emiliano Calvo, Victor J. Chen, Mark S. Marshall, U. Ohnmacht, Scott M. Hynes, (unknown), (unknown), Darlene Barnard, Farhana F. Merzoug, Lysiane Huber, Lisa Kays, Philip W. Iversen, Antonio Calles, (unknown), Aimee Bence Lin, Nicolas Dickgreber, Thomas Wehler, Martin Sebastian	47
8	First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. 2012 ·Journal of Clinical Oncology ·Emiliano Calvo, Karim A. Benhadji, Analía Azaro, Ignacio Durán, Guillem Argilés, Valentina Boni, U. Ohnmacht, Johan Wallin, (unknown), Jordi Rodón	3
9	Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX), followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study 2009 ·Journal of Clinical Oncology ·(unknown), Stephanie E. Combs, Michael Platten, Michael Weller, U. Ohnmacht, C. Stoffregen, D. Thornton	9
10	Reduction of HLA-DR+ Lymphocytes after Treatment with Enzastaurin in Patients with Metastatic Thyroid Cancer 2008 ·Chemotherapy ·Manfred Smetak, Karin Weigang-Koehler, Axel R. Hanauske, U. Ohnmacht, Michael Lahn, Martin Wilhelm, Josef Birkmann	1
11	Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma 2006 ·Lung Cancer ·Jürgen R. Fischer, U. Ohnmacht, Norman Rieger, Marius Žemaitis, C. Stoffregen, Michael Kostrzewa, (unknown), Christian Manegold, Harald Lahm	66
12	Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine 2006 ·Lung Cancer ·Jürgen R. Fischer, U. Ohnmacht, Norman Rieger, Marius Žemaitis, C. Stoffregen, Christian Manegold, Harald Lahm	62
13	Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors 2004 ·Journal of Clinical Oncology ·Claus Bolling, (unknown), (unknown), (unknown), (unknown), (unknown), J. Blatter, H. Depenbrock, U. Ohnmacht, A.-R. Hanauske	4
14	Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors 2004 ·Journal of Clinical Oncology ·Claus Bolling, (unknown), (unknown), (unknown), (unknown), (unknown), J. Blatter, H. Depenbrock, U. Ohnmacht, A.-R. Hanauske	1
15	A phase II trial of pemetrexed in patients with metastatic renal cancer 2003 ·Investigational New Drugs ·R. Thödtmann, Thilo Sauter, S. Weinknecht, L. Weißbach, J. Blatter, U. Ohnmacht, A.-R. Hanauske	19
16	A phase II study of LY355703 (cryptophycine) as first-line therapy for stage IIIb or IV NSCLC subjects: preliminary analysis 2001 ·European Journal of Cancer ·G. Groth, (unknown), U. Ohnmacht, C. Manegold, U. Gatzemeier	2
17	Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer 1999 ·Anti-Cancer Drugs ·K. Possinger, M. Kaufmann, Robert Coleman, (unknown), Martin Helsing, U. Ohnmacht, M. Arning	107
18	Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study 1998 ·Investigational New Drugs ·Diana Lüftner, Bernd Flath, (unknown), H.‐G. Mergenthaler, U. Ohnmacht, M. Arning, (unknown)	22
19	Antidepressant Drug Use: Differences between Psychiatrists and General Practitioners 1997 ·Pharmacopsychiatry ·Regina Dittmann, Michael Linden, (unknown), (unknown), U. Ohnmacht, Holger Weber	11
20	A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumours 1997 ·European Journal of Cancer ·(unknown), (unknown), H. Depenbrock, J. Blatter, U. Ohnmacht, (unknown), A.-R. Hanauske	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact